Purpose: To describe the clinical response, disease control, and treatment safety in prostate cancer patients treated with androgen deprivation therapy (ADT) combined with Di Bella multitherapy (MDB) in patients with prostate cancer.

Materials and Methods: Consecutive evaluable patients with histologically confirmed prostate cancer treated with ADT plus MDB were retrospectively identified from institutional clinical records. Baseline demographic and clinicopathological characteristics were collected and clinical responses were assessed using radiological, biochemical, and clinical followup documentation. Disease control rate (DCR) was defined as remission or stable disease. Continuous variables are summarized as median and interquartile range (IQR) and categorical variables as frequencies and percentages. Exact binomial 95% confidence intervals (CI) were calculated, and exploratory comparisons between disease stages were performed using Fisher’s exact test.

Results: A total of 109 consecutive evaluable patients were included, including 64 localized, 22 regional, and 23 distant stage cases. The median age at treatment initiation was 64 years (IQR: 56–68 years). Disease control was observed in 47 of 64 localized patients (73.4%; 95% CI 61.3–83.1), 16 of 22 regional patients (72.7%; 95% CI 49.8–89.3), and 9 of 23 distant-stage patients (39.1%; 95% CI 19.7–61.5). Disease stage was significantly associated with disease control (Fisher exact test, p=0.008). No grade 3–4 treatment-related toxicities or treatment discontinuations were documented.

Conclusions: ADT combined with MDB is associated with favorable and durable disease control and acceptable tolerability across disease stages. These findings should be considered exploratory and hypothesis-generating and require prospective validation.